Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a CDK4/6 inhibitor as part of combination therapy.

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their ...

Among the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...

On May 15, 2025 , the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market.

CDK4/6 inhibitors show promise but their efficacy varies, highlighting the need for biomarkers. This study explores TRIM4's role in ovarian cancer's response to CDK4/6 inhibitors, revealing that ...

The risk of cardiotoxicity may vary across CDK4/6 inhibitors, according to a study of patients with breast cancer published in the Journal of the National Comprehensive Cancer Network.

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...

A meta-analysis of 18 studies that included a total of 4,899 patients looked at outcomes with subsequent therapies for patients with HR+/HER2- advanced breast cancer that progressed on CDK4/6 ...

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 ...

Arvinas Inc (ARVN) reports a significant revenue increase and outlines strategic moves to extend its cash runway and enhance ...